1. Volcano Announces Schedule of Events at the ACC 2009, Integration into Indec and Medis Software Platforms

    ptca.org Cardiology , Other Business News
    Volcano Announces Schedule of Events at the ACC 2009, Integration into Indec and Medis Software Platforms
    March 27, 2009 -- San Diego -- Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, today announced its presence at the 58th Annual Scientific Sessions of the American College of Cardiology (ACC) conference in Orlando, FL, to be held from March 29th to 31st, 2009. Joe Burnett, Vice President of Marketing at Volcano commented, "Three years ago, you could flip through the ACC program and see a couple of presentations on intravascular assessment using IVUS or FFR. This year, there are more than 50 presentations ...
    Read Full Article

    Login to comment.

    Related Articles

  1. Search:

  2. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology

    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents

    3. Technology:

      Broadband Sources, Probes, Tunable Sources

    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks

  4. Quotes

    1. Three years ago, you could flip through the ACC program and see a couple of presentations on intravascular assessment using IVUS or FFR. This year, there are more than 50 presentations, case reviews and abstracts focused on FFR, IVUS, OCT, Forward-Looking IVUS, and VH® IVUS plaque composition. Word is getting out that more precise guidance during PCI is important, and the sheer number of talks focused on higher resolution tools, highlight the increased demand for access to these technologies. The strategy that relied on angiography alone is evolving to include better confirmation of disease severity and stenting technique. The economic environment that our healthcare system faces is demanding that we target the right patients, and that we get it right the first time.

  5. Topics Mentioned